Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.60 |
| ▸ | FPR2 | P25090 | 4/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27066372 | 1.00 | FPR1 (0.60) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL7127847 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39528 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4592799 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4969844 | 0.99 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL27066369 | 0.95 | FPR1 (0.56) | FPR1FPR2 | |
| SCHEMBL27066371 | 0.95 | FPR1 (0.56) | FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | disclosed |
| US-20150133515-A1 | METHOD FOR INTEGRIN LIGAND DISCOVERY | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2015-05-14 | — | — | US | disclosed |
| US-8911952-B2 | Method for integrin ligand discovery | STC. UNM (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140088034-A1 | NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION | STC.UNM | 2014-03-27 | — | — | US | disclosed |
| US-20130005782-A1 | METHOD FOR INTEGRIN LIGAND DISCOVERY | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2013-01-03 | — | — | US | disclosed |
| WO-2012154975-A2 | NITRIC OXIDE/CGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION | STC.UNM (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2011119732-A2 | METHOD FOR INTEGRIN LIGAND DISCOVERY | STC.UNM (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | FPR1 1/4885FPR2 2/4885LTA4H 55/4885 |
| US-20130005782-A1 | METHOD FOR INTEGRIN LIGAND DISCOVERY | VCAM1, ITGAV, ITGAM | FPR1 251/4885FPR2 247/4885LTA4H 195/4885 |
| US-20150133515-A1 | METHOD FOR INTEGRIN LIGAND DISCOVERY | VCAM1, ITGAV, ITGAM | FPR1 258/4885FPR2 248/4885LTA4H 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.